The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from Business Wire

ARIAD to Hold Conference Call on Monday, September 13, 2010 at 9:00 AM (ET)

Friday, September 10, 2010

ARIAD to Hold Conference Call on Monday, September 13, 2010 at 9:00 AM (ET)17:00 EDT Friday, September 10, 2010 CAMBRIDGE, Mass. (Business Wire) -- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) will hold an investor conference call at 9:00 a.m. (ET) on Monday, September 13, 2010 to provide an update on the clinical development of its investigational pan-BCR-ABL inhibitor, AP24534. Harvey J. Berger, M.D., chairman and chief executive officer, will host the call along with other members of the ARIAD management team. The Company will announce the highlights in a press release to be issued before the market opens on September 13, 2010 prior to the conference call. The live webcast can be accessed by visiting the investor relations section of the Company's website at http://investor.ariad.com. The call can be accessed by dialing 866-730-5763 (domestic) or857-350-1587 (international) five minutes prior to the start time and providing the pass code 10619323. A replay of the webcast will be available on the ARIAD website approximately two hours after completion of the call and will be archived for four weeks. About ARIAD ARIAD's vision is to transform the lives of cancer patients with breakthrough medicines. The Company's mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest and most urgent unmet medical need – aggressive cancers where current therapies are inadequate. ARIAD's lead product candidate, ridaforolimus, is an investigational mTOR inhibitor being developed by Merck Sharpe & Dohme Corp. and is in Phase 3 clinical development in patients with advanced sarcomas. ARIAD's second internally discovered product candidate, AP24534, is an investigational pan-BCR-ABL inhibitor in Phase 1 clinical development in patients with chronic myeloid leukemia. For additional information about the Company, please visit http://www.ariad.com.